What is the typical dosage of Lodine (etodolac) for treating osteoarthritis and rheumatoid arthritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Etodolac (Lodine) Dosage for Osteoarthritis and Rheumatoid Arthritis

For osteoarthritis and rheumatoid arthritis, the recommended starting dose of etodolac (Lodine) is 300 mg twice or three times daily, or 400 mg twice daily, or 500 mg twice daily, with a total daily dose not exceeding 1000 mg. 1

Dosage Recommendations

Osteoarthritis

  • Starting dose options:
    • 300 mg twice daily or three times daily 1
    • 400 mg twice daily 1, 2
    • 500 mg twice daily 1
  • Lower maintenance dose of 600 mg/day may be sufficient for long-term administration 1
  • Clinical trials have demonstrated efficacy with 600-1000 mg/day for osteoarthritis 1, 2

Rheumatoid Arthritis

  • Starting dose options:
    • 300 mg twice daily 1, 3
    • 400 mg twice daily 1
    • 500 mg twice daily 1
  • In clinical trials, 300 mg twice daily was shown to be effective and comparable to piroxicam 20 mg/day 1
  • Long-term studies demonstrated that 500 mg twice daily provided efficacy comparable to ibuprofen 600 mg four times daily 1, 3
  • Minimum effective dose for rheumatoid arthritis is 200 mg daily, though higher doses show better efficacy 4, 3

Important Considerations

Dosage Adjustments

  • Use the lowest effective dose for the shortest duration consistent with treatment goals 1
  • Therapeutic response is sometimes seen within one week, but more often observed by two weeks of therapy 1
  • After satisfactory response is achieved, the patient's dose should be reviewed and adjusted as required 1
  • Doses above 1000 mg/day have not been adequately evaluated in well-controlled clinical trials 1

Special Populations

  • Dosage adjustment is generally not required in patients with mild to moderate renal impairment 1
  • Use with caution in patients with impaired renal function as etodolac, like other NSAIDs, may further decrease renal function 1
  • Consider risks and benefits of pharmacological treatments, particularly in elderly patients and those with comorbidities 5

Administration Considerations

  • When choosing NSAIDs, including etodolac, consider individual risk factors (including age) and monitor for potential gastrointestinal, liver, and cardiorenal toxicity 5
  • For osteoarthritis, consider paracetamol and/or topical NSAIDs before oral NSAIDs 5
  • When using oral NSAIDs like etodolac, consider prescribing alongside a proton pump inhibitor, especially in high-risk patients 5

Clinical Efficacy

  • In osteoarthritis studies, etodolac 400 mg twice daily was as effective as naproxen 500 mg twice daily and nabumetone 1500 mg/day 2
  • In rheumatoid arthritis, etodolac 300 mg twice daily was comparable in efficacy to piroxicam 20 mg/day 1
  • Etodolac has been used in combination with other rheumatoid arthritis treatments including gold, d-penicillamine, chloroquine, corticosteroids, and methotrexate 1

Safety Profile

  • Most common adverse events are digestive system disturbances, which are typically mild to moderate in severity 2
  • Gastrointestinal microbleeding with etodolac has been reported to be comparable to placebo and less than other commonly used NSAIDs 6
  • Like all NSAIDs, etodolac carries risks of gastrointestinal, cardiovascular, and renal adverse effects 5

Remember that etodolac should be used at the lowest effective dose for the shortest possible period of time to minimize potential adverse effects while maintaining therapeutic efficacy 5, 1.

References

Research

Etodolac (Lodine) in the treatment of osteoarthritis: recent studies.

The Journal of rheumatology. Supplement, 1997

Research

Low dose etodolac in rheumatoid arthritis: a review of early studies.

The Journal of rheumatology. Supplement, 1997

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.